Patents by Inventor Lei Ling

Lei Ling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS COMPRISING VARIANTS AND FUSIONS OF FGF19 POLYPEPTIDES
    Publication number: 20190177384
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: December 11, 2018
    Publication date: June 13, 2019
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Modulating Bile Acid Homeostasis in a Subject Having Nonalcoholic Fatty Liver Disease
    Publication number: 20190175697
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: February 21, 2019
    Publication date: June 13, 2019
    Inventors: Lei Ling, Jian Luo
  • Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Modulating Bile Acid Homeostasis in a Subject Having Cirrhosis
    Publication number: 20190175695
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: February 21, 2019
    Publication date: June 13, 2019
    Inventors: Lei Ling, Jian Luo
  • USES AND METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES
    Publication number: 20190060403
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: April 20, 2018
    Publication date: February 28, 2019
    Inventors: Lei Ling, Jian Luo
  • Compositions and Methods for Treatment of Metabolic Disorders and Diseases
    Publication number: 20180362605
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: April 10, 2018
    Publication date: December 20, 2018
    Inventors: Lei Ling, Darrin Anthony Lindhourt
  • Compositions Comprising Variants and Fusions of FGF19 Polypeptides
    Publication number: 20180355007
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: June 25, 2018
    Publication date: December 13, 2018
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • METHODS FOR TREATMENT OF BILE ACID-RELATED DISORDERS
    Publication number: 20180318390
    Abstract: Provided herein are variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FG-F19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). In some embodiments, these variants and fusions modulate bile acid homeostasis, and are useful in treatment of bile acid related and associated disorders. In some embodiments, these variants and fusions have glucose lowering activity, and are useful in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: November 8, 2016
    Publication date: November 8, 2018
    Inventors: Lei Ling, Jian Luo, Hui Tian
  • Methods for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and Diseases
    Publication number: 20180177846
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: February 13, 2018
    Publication date: June 28, 2018
    Inventors: Lei LING, Jian LUO
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having pregnancy intrahepatic cholestasis
    Patent number: 9974833
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: May 22, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject
    Patent number: 9963494
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: May 8, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis
    Patent number: 9925242
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FG-F21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: March 27, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having cholestasis
    Patent number: 9895416
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: February 20, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having nonalcoholic steatohepatitis
    Patent number: 9889178
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: February 13, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having primary sclerosing cholangitis
    Patent number: 9889177
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: February 13, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having error of bile acid synthesis
    Patent number: 9878009
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: January 30, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having bile acid diarrhea or bile acid malabsorption
    Patent number: 9878008
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: January 30, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo
  • METHODS OF USING COMPOSITIONS COMPRISING FUSION VARIANTS OF FGF19 POLYPEPTIDES FOR REDUCING GLUCOSE LEVELS IN A SUBJECT
    Publication number: 20170327551
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: August 1, 2017
    Publication date: November 16, 2017
    Inventors: Lei LING, Darrin Anthony LINDHOUT
  • Methods of using compositions comprising fusion variants of FGF19 polypeptides for reducing glucose levels in a subject
    Patent number: 9751924
    Abstract: The invention relates to methods for and uses in reducing glucose levels in subjects in need thereof with variants and fusions of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics).
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: September 5, 2017
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND DISEASES
    Publication number: 20170182122
    Abstract: Provided herein are variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: May 27, 2015
    Publication date: June 29, 2017
    Inventors: Lei LING, Darrin Anthony LINDHOUT
  • METHODS AND USES FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES
    Publication number: 20170182123
    Abstract: Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.
    Type: Application
    Filed: June 15, 2015
    Publication date: June 29, 2017
    Inventors: Lei LING, Hui TIAN